The first generic drug has become a must for pharmaceutical companies, and 57 first generic drugs have been approved this year

In recent years, the first generic drug is gradually becoming a "contested place"
for a large number of pharmaceutical companies to expand their territory.
According to data, since the beginning of this year, 57 first-class generic drugs have been approved in China, involving 38 companies
.
Among the 57 first generic drugs, Kelun and Hengrui were mostly approved, and 7 and 6 first generic drugs were approved
respectively.
From the perspective of drug types, the varieties of the first generic drugs are mostly varieties
with high technical barriers.
Among them, there are many injections and tablets approved, as many as 19 injections, and 13 oral regular-release dosage forms
.
Specifically, Kelun Pharmaceutical has 16 generic drugs approved for marketing
this year.
Among them, 7 varieties are the first to be evaluated in China, including brimonidine timolol eye drops, ceftriaxone sodium / sodium chloride injection for injection, treagliptin succinate tablets, gadolinol injection, sildenafil citrate oral collapse tablets, medium and long chain fat emulsion / amino acid (16) / glucose (36%) injection, medium and long chain fat emulsion / amino acid (16) / glucose (30%) injection, etc
.
The industry believes that the reason why Kelun Pharmaceutical has become the first big winner in the domestic generic drug track this year is mainly due to the gradual realization of its early layout of generic drug pipeline, and the company's product cluster advantages will be further strengthened
.
Although Hengrui Pharmaceutical has shifted its focus to innovative drugs and international business in recent years, its first generic drug has still gained a lot
.
Among the 10 generic drugs approved this year, as many as 6 are the first generic drugs, including tacrolimus sustained-release capsules, dequafossol sodium eye drops, gadolinol injection, ondansetron oral dissolving film, acetaminophen mannitol injection, and nimodipine oral solution
.
In addition to the above-mentioned first generic approvals, Yangtze River Pharmaceutical, Beijing Hanmei Pharmaceutical, Yichang Renfu Pharmaceutical, Shutaishen (Beijing) Biological Products, Weigao Termo (Weihai) Medical Products, Qilu Pharmaceutical, Hainan Puli Pharmaceutical and China Biologics also have two first-class generic drugs approved for marketing
this year.
In addition, more than 20 pharmaceutical companies such as Chengdu Beite Pharmaceutical, Hainan Simcere Pharmaceutical, Jiangsu Haosen Pharmaceutical and Jichuan Pharmaceutical have also successfully won the first generic drug
.
In fact, the first generic drug has always been one of the key points of the R&D layout of domestic pharmaceutical companies, with the upgrading and development of China's pharmaceutical industry, the R&D strength of domestic pharmaceutical companies has gradually improved, and the first generic drug has gradually become a must for
pharmaceutical companies.
In recent years, with the continuous advancement of drug review reform and the intensification of competition in the innovative drug market, such drugs are becoming a sharp weapon for market competition, and the first imitation of large varieties has become the focus
of attention in the industry.
The industry expects that in the future, under the background of the continuous advancement of policies such as volume procurement, medical insurance negotiations, and the increasing efforts of the state to encourage patent challenges, more and more domestic first generic drugs will appear, and the research and development of new dosage forms of generic drugs, children's drugs, rare diseases, etc.
will gradually become a trend
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.